Login | Register

Lilly Terminates Alzheimer’s Drug Trial, Citing Abnormal Liver Tests

Eli Lilly's Phase II study for an investigational drug for Alzheimer's disease has been terminated due to abnormal liver biochemical tests. The company says that clinical study investigators have been informed. The compound in question, a beta secretase (BACE) inhibitor called LY2886721, was being tested as a once-daily therapy to slow down Alzheimer's disease progression. Jan M...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *